



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Susumu MUTO et al.

Group Art Unit : 1615

Appl. No. : 10/516,294

(U.S. National Stage of PCT/JP03/07119)

I.A. Filed : June 5, 2003

Examiner : Not Yet Assigned

For : NF-KB ACTIVATION INHIBITORS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and further to the Information Disclosure Statement filed on February 24, 2006, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification and in the International Search Report of commonly assigned U.S. Application No. 10/515,623. The following is a list of additional documents cited in the above noted documents:

U.S. Patent No. 3,331,874;

G.B. Patent No. 996,074;

MATSUZAKI, et al., "Amer. J. Reproductive Immunol.", 1986, Vol. 40, page 291-294;

UCHIIDE, et al., "Nikkei Medical," 2002, No. 415, page 28, with English translation;

UCHIIDE, et al., "Fertility and Sterility," 2002, Vol. 78, No. 4, page 782-786; and

CHEGINI, "Frontiers in Bioscience," 2002, Vol. 7, page e91-115.

Further to 37 C.F.R. §1.98, a copy of the U.S. patent is not enclosed. However, if a copy is needed, the Examiner is respectfully requested to contact the undersigned.

Applicants respectfully request that the Examiner consider the above material and cite the same. Copies of the above-noted documents and articles are attached hereto and all of the documents are listed on the attached PTO-1449 Form. The Examiner is requested to initial the appropriate spaces on the attached Form and to return a copy of the initialed Form to Applicants with the next official communication in the present application.

Applicants note that an Office Action on the merits has not issued in the present application, and thus no fee is believed necessary to ensure consideration of the submitted material. However, if any fee is necessary for consideration of this Information Disclosure Statement, the undersigned hereby authorizes the charging of any fee necessary for the consideration of this statement, including any payment under 37 C.F.R. §1.17 (p), to Deposit Account No. 19-0089.

Should the Examiner have any questions, the Examiner is invited to contact the undersigned at the below-listed telephone number.

Respectfully Submitted,
Susumu MU TO et al.



Bruce H. Bernstein
Reg. No. 29,027

March 7, 2006

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Arnold Turk
Reg. No. 33094

